The global tumor profiling market size was estimated at USD 10.73 billion in 2017 and is expected to register a CAGR of 8.8% during the forecast period. Cancer tumor profiling (CTP) is done to evaluate the metabolism, properties, and mutations in a tumor, which can aid in discovery of effective therapies.
Drugs that target these mutated kinases can be discovered and developed according to changes in genes. Cancer tumor profiling is seen as a necessity to improve the sensitivity of kinase targeting drugs as they depend on the genetic makeup of individual tumors. Thus, these mutated tumor DNA profiles help design specific anti-cancer therapies.
Research support and funding for cancer research have increased with the discovery of advanced techniques that can potentially reduce the time taken for detection and identification of tumors or the stage of advancements. Moreover, high investments by biotechnology companies have been observed in development of novel therapies and new drug designing techniques.
Next Generation Sequencing (NGS) technology has witnessed rapid adoption as it facilitates whole genome sequencing. In addition, the technology is used for clinical profiling of cancer tumors such as screening, diagnosis, and novel drug discovery.
Genomic microarrays are one of the most powerful technologies that can be used for gene-expression. In the last 10 years, there has been tremendous growth in microarray application in gene-expression profiling. This has contributed to cancer classification, gaining deeper insights on pathogenesis, and discovery of a large number of cancer biomarkers.
Key techniques include omics sciences such as genomics, proteomics, epigenetics, and metabolomics. Cancer mortality rate is significantly high worldwide and cancer therapy is the most targeted field in the development of personalized medicine.
The advent of high-end technologies has enabled a possibility of detailed omics analysis of mechanisms at a molecular level, rendering a clear picture of tumor biology. These sciences have helped identify clinically feasible mutations and indicated cancers and gene and protein expression patterns.
In most of cases, cancer is known to reoccur due to continuous alterations in the genetic makeup. Genomics plays a crucial role in detection of these genetic variations in cases of recurrence. These genomic platforms have proven to be advantageous as they lead to cost savings, improve screening time, and can help in identifying a larger size of evaluated genome. These factors are likely to encourage usage of omics sciences for tumor profiling in the coming years.
Cancer tumor profiling finds application in personalized medicine, research, discovery of biomarkers, and development of screening and diagnostic techniques. Tumor profiling is most commonly used in development of precision medicine, which suits the genetic makeup of a patient to improve healing and recovery time.
There has been overwhelming demand for personalized medicine owing to advancements in technology used in treatment methods and research. This procedure is also used in oncology research and discovery of biomarkers, during the processes of drug design, discovery, and development. The segment is expected to hold the largest share in the global cancer tumor profiling market and also exhibit the fastest growth rate by 2025.
With rapid growth in gene profiling technologies and individualized targeted therapies, biomarkers are playing an important role in designing a drug regimen for cancer patients. Genome-based prognostic biomarkers are currently in use, which can be used in prognosis of several cancer types at clinical stages and also help develop drugs and therapies. However, researchers argue that the large gap between biomarker discovery stage and their clinical conversion is being hindered by challenges in conversion procedures.
Obtaining information about the genomic build of a tumor is considered as the most important step in the prognosis, diagnosis, and treatment of cancer. Next-generation sequencing (NGS) is an advanced sequencing technology that can be used for precise genomic sequencing of tumor DNA.
The interpreted data helps in the estimation of tumor purity and extent of disease advancement at a much faster rate. The main advantage of NGS is that it allows whole exome sequencing, which aids in the examination of all protein-coding regions of the human genome. It also allows for whole genome sequencing, which can be helpful in analyzing regions of protein-coding and non-coding in the human genome.
Other technologies such as microarrays are yet to be widely accepted for diagnosis and classification of cancers. Despite increased research activity in microarray technology development, only a few approaches have been refined and are being utilized for analysis of tumors and diagnostic data. Microarray technology is not limited to clinical labs but can improve the accuracy of classical diagnostic techniques by providing novel tumor-specific biomarkers.
North America is estimated to account for the largest share in terms of revenue owing to the presence of major players and rapid advances in technology. In addition, high prevalence of cancer and increased research in oncology to identify and discover novel therapy for treatment will benefit market growth. Rapid uptake of advanced technologies by firms manufacturing these diagnostics kits is another significant factor contributing to the regional market’s large share.
Asia Pacific is a lucrative region and is expected to steady significant growth over the forecast period due to low penetration rate, availability of massive untapped markets, and a large population pool.
Competition in this market is fierce owing to the presence of many small and big companies trying to gain a major share by focusing on automation instruments and patented technique development for cancer profiling.
Large companies such as Illumina Inc.; Qiagen N.V.; Genomic Health; and Neogenomics Inc. lead the market with a significant share. Other key industry participants include HTG Molecular Diagnostics, Inc.; Caris Life Sciences; Helomics Corporation; Oxford Gene Technology; Nanostring Technologies; Ribomed Biotechnologies Inc.; GenomeDX; Guardant Health; and Foundation Medicine.
Continued research and technological advancements are expected to push companies to offer products at economical prices in emerging regions as an initiative to capture a larger market share.
Market size value in 2020
USD 14.6 billion
Revenue forecast in 2025
USD 21.1 billion
CAGR of 8.2% from 2018 to 2025
Base year for estimation
2014 - 2016
2018 - 2025
Revenue in USD Million and CAGR from 2018 to 2025
Revenue forecast; company share; competitive landscape; growth factors and trends
Technique, application, technology, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; China; Japan; Brazil; South Africa
Key companies profiled
Illumina Inc.; Qiagen N.V.; Genomic Health; Neogenomics Inc., Life Sciences; Oxford Gene Technology; Nanostring Technologies; Ribomed Biotechnologies Inc.; GenomeDX; Guardant Health; Foundation Medicine.
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global tumor profiling market report based on technology, technique, application, and region:
Technique Outlook (Revenue, USD Million, 2014 - 2025)
Technology Outlook (Revenue, USD Million, 2014 - 2025)
In Situ Hybridization
Application Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
b. The global cancer tumor profiling market size was estimated at USD 13.2 billion in 2019 and is expected to reach USD 14.6 billion in 2020.
b. The global cancer tumor profiling market is expected to grow at a compound annual growth rate of 8.2% from 2020 to 2025 to reach USD 21.1 billion by 2025.
b. Sequencing Techniques dominated the cancer tumor profiling market with a share of 23% in 2019. This is attributable to advent of 4th generation of sequencing and technological advancements in its sample preparation protocols to simplify the process.
b. Some key players operating in the telemedicine market include Illumina Inc.; Qiagen N.V.; Genomic Health; Neogenomics Inc., Life Sciences; Oxford Gene Technology; Nanostring Technologies; Ribomed Biotechnologies Inc.; GenomeDX; Guardant Health; and Foundation Medicine.
b. The key factor driving the market growth include increasing implementation of OMICs (genomics, proteomics, metabolomics, and epigenetics) in the development of personalized medicine for cancer management.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."